Bruce Cozadd: Yes, Greg, thanks for the question. And always interesting to learn from your past corp dev deals as you consider your important strategy going forward. In the Celator deal, we brought in a near-term launch with Vyxeos now on the market in the US and abroad as well as the CombiPlex platform, which we continue to see as a source of other interesting products for our future development and commercialization. And I’ll just remind you that Vyxeos remains under study in other areas inside and outside AML that we think may allow us to broaden use in the future. So Rob, maybe talk a little bit about how Vyxeos is being studied right now? And then maybe, Renee, you can jump in with the prompt of how we think about different approaches to corp dev moving forward. Rob?
Rob Iannone: Sure, Bruce, thanks. So it’s being studied in a number of different ways through ISD’s collaborations with major cancer centers and cooperative groups as well as in some ongoing studies that we’re conducting. And I would just highlight a couple of things. One would be in combinations that could be highly relevant, like combinations with venetoclax. Those trials are ongoing. And also trials that would seek to extend the indication to a broader group of patients, such as the cooperative group with AMLSG, which is not just the high-risk patients but more broadly, front line.
Renée Galá: Yes. And then I’ll just cap it out in terms of business development going forward. So if I just look at the Zanidatamab deal in terms of how we structured it we are looking to ensure as we enter into transactions that are meeting our strategic objectives that we’re also looking to balance — strike the right balance between monetary upfront financial outlays with risk and other value inflection points. Certainly, with that transaction, we are excited to be able to leverage the team at Zymeworks in terms of continuing to drive these studies in the near term and looking at creative ways that we can continue to leverage our partners for their superpowers and skills that they’re bringing to the table while also continuing to advance our strategy.
And in particular, with this transaction, we were pleased to be able to strike that balance with the financials and the value inflection points, not only in the upfront and how we’ve structured that. But also as we look forward, and look at the milestones that were primarily driven by regulatory and future commercial value inflection points. So with the optionality that we have going forward, both from a financial perspective as well as having a broader business now, we’ll continue to look at creative ways to structure transactions to have win-win outcomes for both Jazz and our patients and shareholders as well as our partners.
Operator: At this time, I am showing no further questions. I would now like to turn the conference back to Bruce Cozadd for closing remarks.
Bruce Cozadd: Thanks, Michelle. So thanks for joining us, everyone. We look forward to a strong finish to 2022 and remain focused on achieving Vision 2025. And I’d just like to close today’s call by recognizing our Jazz colleagues for their commitment to delivering new therapeutic options to patients and want to thank our partners and shareholders for their continued collaboration and support. Have a good evening, everyone.
Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.
